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It has been shown that infection of GB virus B (GBV-B), which is closely related to hepati-
tis C virus, develops acute self-resolving hepatitis in tamarins. In this study we sought
to examine longitudinally the dynamics of viral and immunological status following GBV-B
infection of marmosets and tamarins. Surprisingly, two of four marmosets but not tamarins
experimentally challenged with GBV-B developed long-term chronic infection with ﬂuctu-
ated viremia, recurrent increase of alanine aminotransferase and plateaued titers of the
antiviral antibodies, which was comparable to chronic hepatitis C in humans. Moreover,
one of the chronically infected marmosets developed an acute exacerbation of chronic
hepatitis as revealed by biochemical, histological, and immunopathological analyses. Of
note, periodical analyses of the viral genomes in these marmosets indicated frequent and
selective non-synonymous mutations, suggesting efﬁcient evasion of the virus from antivi-
ral immune pressure.These results demonstrated for the ﬁrst time that GBV-B could induce
chronic hepatitis C-like disease in marmosets and that the outcome of the viral infection
and disease progression may depend on the differences between species and individuals.
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INTRODUCTION
Among the known viruses, GB virus B (GBV-B) is closely related
to hepatitis C virus (HCV), with 25–30% homology at the amino
acid level, and is tentatively classiﬁed in Hepacivirus genus of Fla-
vivirus family (Muerhoff et al., 1995; Simons et al., 1995; Ohba
et al., 1996). Due to limited epidemiological analyses, the natural
host(s) and prevalence of GBV-B have remained to be determined.
Hepatitis C virus is a major causative agent for non-A, non-B
hepatitis.HCV is globally disseminated and estimated to be carried
by more than 170 million people (Chisari, 2005; Lavanchy, 2009).
MostHCV-infected individuals develop chronic liver diseases such
as liver cirrhosis and hepatocellular carcinoma (Hoofnagle, 1997;
Seeff and Hoofnagle, 2002; Rehermann and Nascimbeni, 2005).
Since standard therapy with PEGylated interferon and ribavirin
is effective for only about 50% of patients, it is crucial to develop
more effective therapeutics (Feld andHoofnagle, 2005;Melnikova,
2008). The only validated animal model for HCV infection is
Abbreviations: ALT, alanine aminotransferase; GBV-B, GB virus B; HCV, hepatitis
C virus; HE, hematoxylin and eosin; p.i., post infection.
the chimpanzees. This model has been valuable for determin-
ing important aspects of this disease, including the relationship
between the virus and the antiviral immune responses of the host
and the process of viral pathogenesis (Bukh, 2004; Akari et al.,
2009; Boonstra et al., 2009). However, chimpanzees are endan-
gered and present ethical complications and the availability of
these experimental animals is severely restricted.
When tamarins (members of the New World monkeys) are
infected with GBV-B, they generally develop acute viremia and
self-resolving hepatitis as indicated by increases in the levels of
serum enzymes such as alanine aminotransferase (ALT) (Bukh
et al., 1999; Beames et al., 2000; Beames et al., 2001; Sbardellati
et al., 2001; Lanford et al., 2003; Martin et al., 2003; Bright et al.,
2004; Jacob et al., 2004; Nam et al., 2004; Kyuregyan et al., 2005;
Ishii et al., 2007;Weatherford et al., 2009). Thus, themonkeys have
been proposed as a surrogate model of HCV infection of chim-
panzee and humans.However, amajor hurdle for the development
of a monkey-based surrogate model is the difﬁculties encountered
in obtaining chronically infectedmonkeys that exhibit progression
of chronic hepatitis C-like diseases (Martin et al., 2003; Nam et al.,
2004; Takikawa et al., 2010).
www.frontiersin.org December 2011 | Volume 2 | Article 240 | 1
Iwasaki et al. Chronic hepatitis C-like diseases in marmosets
It has recently been shown that marmosets, another mem-
ber of New World monkeys, are susceptible to GBV-B infec-
tion and develop relatively lower levels of acute viremia
(105–108 copies/ml) as compared with that in tamarins (107–
1010 copies/ml) (Lanford et al., 2003; Bright et al., 2004; Woollard
et al., 2008; Weatherford et al., 2009), although it remains elusive
whether the marmosets could permit persistent GBV-B infection.
Considering that the viral loads in the acute phase of experimental
HCV infection of chimpanzees that consequently develop persis-
tent infection are generally 107 copies/ml or less (Fernandez et al.,
2004; Bukh et al., 2008), it is possible that the lower viral loads
in the acute phase is preferable for the establishment of viral per-
sistency. We thus initiated studies of the dynamics of viral and
immunological status following GBV-B infection of tamarins and
marmosets in a longitudinal follow-up study. We show here for
the ﬁrst time that GBV-B infection produces a chronic and pro-
gressive hepatitis C-like disease in marmosets as demonstrated by
ﬁbrosis and a recurrent ALT increase and that one of the mar-
mosets experienced acute exacerbation of chronic hepatitis as
indicated by piecemeal necrosis and an ALT ﬂare >4 years after
infection.
MATERIALS AND METHODS
ANIMALS
Adult red-handed tamarins (Saguinus midas) and common mar-
mosets (Callithrix jacchus) were housed in individual cages at the
Tsukuba Primate Research Center. All animal studies were con-
ducted in accordance with the protocols of experimental proce-
dures that were approved by the AnimalWelfare and Animal Care
Committees of the National Institute of Biomedical Innovation
and the National Institute of Infectious Diseases.
GBV-B INFECTION IN TAMARINS AND MARMOSETS
GBV-B infectious serum obtained from a tamarin (1.3× 109 viral
RNA copies per inoculum) was injected into each tamarin and
marmoset intrahepatically as previously described (Ishii et al.,
2007). We conﬁrmed that the inoculum contained no mutations
as comparedwith the original sequence. Of note, an anti-luciferase
siRNA in a cationic liposome formulationwas administered to one
of the marmosets (Cj05-002) 2 days before the infection, which
was performed as previously described (Yokota et al., 2007). Blood
samples were periodically collected from the femoral vein of each
animal under anesthesia and the plasma samples were evaluated
for GBV-B genomic RNA,ALT, and antibodies against GBV-B core
and NS3 proteins.
QUANTIFICATION OF GBV-B GENOMIC RNA
GBV-B RNA was isolated from the plasma samples by
using a QIAamp MinElute Virus Spin kit (QIAGEN) and
was quantiﬁed by real-time PCR using the 5′-exonuclease
PCR (TaqMan) assay system (Ishii et al., 2007). The
primers 558F [5′-AACGAGCAAAGCGCAAAGTC] and 626R [5′-
CATCATGGATACCAGCAATTTTGT] and the probe 579P [5′-
FAM-AGCGCGATGCTCGGCCTCGTA-TAMRA] (Beames et al.,
2000) were obtained from Sigma-Aldrich. The cutoff value was
103 copies/ml. All the specimens were evaluated in duplicate and
the average values were calculated.
DETECTION OF ANTIBODIES AGAINST GBV-B CORE AND NS3
PROTEINS BY ELISA
Tamarin and marmoset plasma samples were evaluated for anti-
GBV-B core and NS3 antibodies by ELISA as described previously
(Ishii et al., 2007).
HISTOPATHOLOGICAL AND IMMUNOHISTOCHEMICAL ANALYSES
Liver samples obtainedbynecropsy from theGBV-B-infectedmar-
moset were examined histopathologically as previously described
(Ishii et al., 2007). For standard histological examination, the
sections were subjected to hematoxylin and eosin (HE) stain-
ing. Masson’s trichrome staining was also performed to estimate
the development of ﬁbrosis according to a standard laboratory
protocol. To detect the viral protein in tissues, we employed a
mouse anti-core monoclonal antibody, 5A10, that we generated.
In brief, Mice were immunized with the GBV-B core protein
expressed in E. coli (Ishii et al., 2007). Hybridoma cells produc-
ing an anti-core mAb were screened by both the core-expressing
293T cells and the liver sections of an acutely GBV-B-infected
tamarin. Liver samples were ﬁxed in 10% neutral buffered for-
malin and embedded in parafﬁn wax. Sections were deparaf-
ﬁnized by pretreating with 0.5% periodic acid and then sub-
jected to antigen retrieval with citric acid buffer and heating in
an autoclave for 10min at 121˚C. The sections were then incu-
bated free ﬂoating in primary antibody solution (5A10; 1:50
dilution) overnight at 4˚C. Following brief washes with wash
buffer, the sections were sequentially incubated with a biotiny-
lated goat anti-mouse IgG (1:400 dilution), followed by addition
of a streptavidin–biotin–horseradish peroxidase complex (sABC
kit; DAKO, Denmark). Immunoreactive elements in the sections
were visualized by treatment with 3,3′-diaminobenzidine tetrox-
ide (Dojin Kagaku, Japan), together with counterstaining with
hematoxylin.
DETERMINATION OF THE GBV-B SEQUENCE
Viral RNA was isolated from the plasma of GBV-B-infected
marmosets as described above. GBV-B cDNA was synthesized
using SuperScript reverse transcriptase III (Invitrogen) with
random hexamer primers (Invitrogen). The resulting cDNAs
were used to obtain PCR ampliﬁcation products of lengths
of 0.5–1.0 kb, using GBV-B-speciﬁc primers and LA-Taq DNA
polymerase (TaKaRa). The PCR products were then puriﬁed
from the gel using a QIA-quick gel extraction kit (QIAGEN),
and the puriﬁed amplimers were sequenced directly using a
CEQ-2000XL analysis system (Beckman) with a DTCS quick
start kit and GBV-B-speciﬁc primers according to the manu-
facturer’s instructions. Sequence data were analyzed using the
Sequencher 4.8 (Gene Codes) and Mac Vector 10.6 (MacVec-
tor) software packages. The GenBank accession numbers of
the viral genome sequences in each time point are as fol-
lows: AB630358, AB630359, and AB630360 for 45, 104, and
135weeks after infection in Cj05-002; AB630361, AB630362,
AB630363, and AB630364 for 33, 88, 141, and 229weeks after
infection in Cj05-004, respectively. Throughout this article,
the amino acids are numbered according to the full-length
genome sequence of isolate pGBB (GenBank accession number
AF179612).
Frontiers in Microbiology | Virology December 2011 | Volume 2 | Article 240 | 2
Iwasaki et al. Chronic hepatitis C-like diseases in marmosets
RESULTS
GBV-B INFECTION IN TAMARINS AND MARMOSETS
Four tamarins and four marmosets were intrahepatically inocu-
lated with GBV-B and the growth kinetics and pathogenesis of the
virus were compared. In tamarins, the peak viral loads in plasma
reached 109–1010 copies/ml in the acute phase and the viremia was
maintained for an average of 3months in parallel with increases
in plasma ALT levels (Figure 1A). Antibodies reactive with the
viral core and NS3 proteins were developed in all of the tamarins
as the plasma viral loads were reduced and the antibody titers
reached maximum levels concurrently with the complete loss of
detectable viral RNA (Figure 1A). In contrast, two of four mar-
mosets infectedwithGBV-B developed chronic infectionwhile the
others exhibited a phenotype similar to that of the tamarins (i.e.,
subacute clearance of the viremia followed by antibody responses).
One exception is that lower plasma viral loads (107–108 copies/ml)
were observed in the marmosets relative to those of the tamarins
FIGURE 1 | Infection profiles until week 70 p.i. of tamarins (A) and
marmosets (B) inoculated intrahepatically with GBV-B infectious
serum obtained from a tamarin. Plasma samples periodically obtained
from the monkeys were evaluated for the copy numbers of GBV-B genomic
RNA (green shaded area), ALT levels (red circles), and the antibody titers
against GBV-B core and NS3 (blue and yellow triangles, respectively).
(Figure 1B). The details of the chronically infected marmosets are
described below.
Case 1: Cj05-002 (Figures 1B and 2). The viral RNA was
undetectable until week 4 post infection (p.i.) and then grad-
ually increased to a peak at week 18 p.i. (3× 107 copies/ml).
Subsequently, this case retained intermittent viremia during the
observation period of week 180 p.i.,while the intervals between the
viremia phases were prolonged. Importantly, the titers of anti-core
and anti-NS3 antibodies reached a persistent plateau at 6months
and 1 year p.i., respectively. In addition,ALT levelswere recurrently
increased without observation of other clinical symptoms.
Case 2: Cj05-004 (Figures 1B and 2). During the acute phase
of infection, the level of viremia was relatively low and transient,
followed by a 1-year period when the virus was essentially unde-
tectable. Irrespective of the very low viral load, the titer of anti-NS3
but not anti-core antibody steadily increased and reached a plateau
at week 42 p.i. Moreover, an occasional but obvious increase in
the level of ALT was observed during this period. We thus sus-
pected that antigenic stimulation by a lower level of viral growth
in the liver,which remained belowdetectable levels in blood,might
lead to the induction of the anti-NS3 antibody and the recurrent
ALT increase. Subsequently, viremia became detectable at week 58
p.i. and 104–105 copies/ml of the viral RNA persisted until week
108 p.i. Thereafter, an abrupt increase of the anti-core antibody
was detected, concomitant with augmentation of the viral load of
105.5 copies/ml on average and recurrent increases in theALT level.
Eventually, the individual was euthanized at week 229 p.i. because
of poor prognosis since theALT value drastically increased by 161-
fold, which was accompanied by a dramatic decrease of platelet
counts and a deteriorating general status. Histopathological analy-
ses of the necropsy samples demonstrated that the liver developed
diffuse piecemeal necrosis with inﬁltration of lymphocytes and
FIGURE 2 | Profiles of the marmosets persistently infected with GBV-B.
Plasma samples periodically obtained from the marmosets were evaluated
for the copy numbers of GBV-B genomic RNA (green shaded area), ALT
levels (red circles), and the antibody titers against GBV-B core and NS3 (blue
and yellow triangles, respectively). The cruciate mark in Cj05-004 indicates
that the individual was euthanized due to a poor prognosis at week 229 p.i.
At that time, the ALT value in plasma had increased by 161-fold.
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formation of lymphoid follicles (Figure 3A, Appendix). The viral
load in the liver was relatively high (3.8× 104 copies/mg tissue
weight), which was similar to the viral load observed for tamarins
acutely infected with GBV-B (Ishii et al., 2007). The high viral
load in the liver was consistent with a large number of granular
positive signals for the core protein, which was in similar manner
with the core protein of HCV (Miyanari et al., 2007), as immunos-
tainedwith an anti-GBV-B coremonoclonal antibody (Figure 3B).
Notably,Masson trichrome staining (Figures 3C,D) aswell as Elas-
tica van Gieson staining (Appendix) demonstrated that the liver
also developed diffuse and abundant ﬁbrosis. The disease of this
marmoset was therefore diagnosed as a case of acute exacerbation
of progressive chronic hepatitis by GBV-B infection.
ANALYSIS OF MUTATIONS IN GBV-B GENOMES
Next, we determined the dominant sequence of the viral genomes
at weeks 45, 104, and 135 p.i. in Cj05-002 and weeks 33, 88,
141, and 229 p.i. in Cj05-004. As seen in Figure 4A, it was
found that there was no speciﬁc region in which extensive
nucleotide mutations occurred throughout the study periods and
that the nucleotide mutation rates were 1.9–2.9× 10−3 and 1.5–
3.6× 10−3 changes per site per year in Cj05-002 and Cj05-004,
respectively (Table 1). In terms of amino acid substitution, we
observed the following: (i) several back or sequential mutations
(G250V>A, S731L> S, E2346G> E in Cj05-002; V254A>V,
I285V> I, L495S> L, T735A>T, F2135L> F> S in Cj05-004)
in both marmosets; (ii) highly selective non-synonymous muta-
tions that were remarkable in E1, but such mutations were rarely
observed in core (Figures 4 and 5); and (iii) the non-synonymous
mutation rates were 1.8–4.0× 10−3 and 2.1–4.6× 10−3 substi-
tutions per site per year in Cj05-002 and Cj05-004, respectively
(Figures 4 and 5; Table 2). (iv) The non-synonymous changes
detected mainly in NS5A and NS5B in both animals were also
observed in a number of previous reports (Simons et al., 1995;
Bukh et al., 1999; Sbardellati et al., 2001; Martin et al., 2003;
FIGURE 3 | Histopathological and immunohistochemical analyses of
the liver from Cj05-004 at week 229 p.i. HE staining (A),
immunohistochemical staining for the core protein of GBV-B (B), and
Masson’s trichrome staining (C,D) are shown.
Nam et al., 2004; Kyuregyan et al., 2005; Weatherford et al., 2009;
Takikawa et al., 2010). It may be reasonable to consider that the
molecular clone we employed (Bukh et al., 1999) was derived from
aminor clone of mixed populations and emergence of a newmuta-
tions easily occurred as amechanismof GBV-Badaptation to anew
host, while it is also possible that “consensus” non-synonymous
changes were due to either a result of a selection of the pre-existent
minor variants. Taken together, these results suggest that efﬁcient
FIGURE 4 | Mutations in the viral genome sequences amplified from
plasma of the marmosets persistently infected with GBV-B. (A)
Positions of the nucleotide mutations in the viral genome sequences at
multiple time points (at weeks 45, 104, and 135 in Cj05-002 and weeks 33,
88, 141, and 229 in Cj05-004) are illustrated as bars. (B,C) Positions of the
non-synonymous mutations in the viral genome sequences at multiple time
points are shown. (B) Cj05-002; (C) Cj05-004. Positions of the mutations
that had been identiﬁed in previous reports are indicated as black, while
those unidentiﬁed previously are shown as blue. Red squares illustrate back
or sequential mutations.
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Table 1 | Summary of the nucleotide substitutions in GBV-B genome sequences amplified from plasma of the marmosets persistently infected
with GBV-B.
Genomic region nt position No. (%) of nt differences
Cj05-002 Cj05-004
45weeks 104weeks 135weeks 33weeks 88weeks 141weeks 229weeks
5′UTR 1–445 2 (0.45) 3 (0.67) 2 (0.45) 1 (0.22) 0 (0) 3 (0.67) 0 (0)
Core 446–913 0 (0) 1 (0.21) 1 (0.21) 1 (0.21) 4 (0.85) 2 (0.43) 3 (0.64)
E1 914–1489 1 (0.17) 3 (0.52) 0 (0) 1 (0.17) 3 (0.52) 1 (0.17) 2 (0.35)
E2 1490–2449 0 (0) 5 (0.52) 1 (0.10) 0 (0) 2 (0.21) 1 (0.10) 6 (0.63)
p13 2450–2641 2 (1.04) 1 (0.52) 2 (1.04) 2 (1.04) 1 (0.52) 0 (0) 1 (0.52)
NS2 2642–3265 1 (0.16) 5 (0.80) 1 (0.16) 1 (0.16) 4 (0.64) 1 (0.16) 2 (0.32)
NS3 3266–5125 1 (0.05) 4 (0.22) 3 (0.16) 0 (0) 5 (0.27) 6 (0.32) 3 (0.16)
NS4A 5126–5290 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0.61)
NS4B 5291–6034 0 (0) 0 (0) 2 (0.27) 0 (0) 1 (0.13) 0 (0) 0 (0)
NS5A 6035–7267 6 (0.49) 4 (0.32) 2 (0.16) 4 (0.32) 4 (0.32) 2 (0.16) 3 (0.24)
NS5B 7268–9037 4 (0.23) 5 (0.28) 3 (0.17) 2 (0.11) 10 (0.56) 1 (0.06) 4 (0.23)
Total 9037 17 (0.19) 31 (0.34) 17 (0.19) 12 (0.13) 34 (0.38) 17 (0.19) 25 (0.28)
Mutation rate/year 2.2×10−3 3.0×10−3 3.2×10−3 2.1×10−3 3.6×10−3 1.8×10−3 1.6×10−3
Table 2 | Summary of the amino acid substitutions in GBV-B genome sequences amplified from plasma of the marmosets persistently infected
with GBV-B.
Amino acid region aa position No. (%) of aa differences
Cj05-002 Cj05-004
45weeks 104weeks 135weeks 33weeks 88weeks 141weeks 229weeks
Core 1–156 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0.64)
E1 157–348 1 (0.52) 2 (1.04) 0 (0) 1 (0.52) 3 (1.56) 1 (0.52) 1 (0.52)
E2 349–613 0 (0) 2 (0.63) 0 (0) 0 (0) 1 (0.31) 0 (0) 4 (1.25)
P13 669–732 1 (1.56) 1 (1.56) 1 (1.56) 1 (1.56) 0 (0) 0 (0) 0 (0)
NS2 733–940 1 (0.48) 2 (0.96) 0 (0) 1 (0.48) 2 (0.96) 0 (0) 0 (0)
NS3 941–1560 1 (0.16) 0 (0) 1 (0.16) 0 (0) 2 (0.32) 2 (0.32) 1 (0.16)
NS4A 1561–1615 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1.82)
NS4B 1616–1863 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
NS5A 1864–2274 4 (0.97) 2 (0.49) 0 (0) 3 (0.73) 1 (0.24) 2 (0.49) 3 (0.73)
NS5B 2275–2864 2 (0.34) 3 (0.51) 1 (0.17) 1 (0.17) 5 (0.85) 1 (0.17) 1 (0.17)
Total 2864 10 (0.38) 12 (0.42) 3 (0.10) 7 (0.24) 14 (0.49) 6 (0.21) 12 (0.42)
Mutation rate/year 4.0×10−3 3.7×10−3 1.8×10−3 3.9×10−3 4.6×10−3 2.1×10−3 2.5×10−3
and selective evasion from immune pressure in the twomarmosets
resulted in long-term persistent GBV-B infection accompanied by
subsequent chronic hepatitis.
DISCUSSION
In this study, we show for the ﬁrst time that GBV-B is capable of
eliciting a chronic and progressive hepatitis C-like disease in mar-
mosets. Evidence for this condition is demonstrated by long-term
persistent GBV-B infection, recurrent ALT increase, and ﬁbrosis.
Moreover, one of the chronically infected marmosets developed
acute exacerbation of chronic hepatitis as indicated by diffuse
piecemeal liver necrosis and an ALT ﬂare, which is seen in patients
with viral hepatitis (Perrillo, 1997). While the usefulness of the
monkey model as a surrogate model for HCV infection has been
under debate due to the virtual inability of GBV-B to cause chronic
hepatitis C-like disease in tamarins, the present data demonstrate
that the ability of GBV-B to induce the chronic disease is likely
to be inherent depending on the differences between species and
individuals.
It has been reported that tamarins generally permit exten-
sive replication of GBV-B in the subacute phase of infection and
develop acute hepatitis as shown by signiﬁcant increases of serum
enzymes such as ALT and isocitrate dehydrogenase. The viral load
in marmosets seems to be lower than in tamarins (Lanford et al.,
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2003; Bright et al., 2004; Woollard et al., 2008; Weatherford et al.,
2009). A recent report indicated that marmosets exhibit suscepti-
ble and partially resistant phenotypes upon infection with GBV-B
(Weatherford et al., 2009). Consistent with this ﬁnding, the present
results also showed that the marmosets appeared to exhibit two
phenotypes (Figure 1B). Importantly, the long-term persistent
GBV-B infection was established in the marmosets with lower
viral loads during the initial weeks p.i. (Figure 1B; Cj05-002 and
Cj05-004). This suggests that the mild viral growth in the mar-
mosets with a “partially resistant” phenotype is critical for the
establishment of the chronic infection. Of note, the viral growth
was undetectable until week 6 p.i. in Cj05-002, owing to unex-
pected interferon responses that were induced by administration
of an anti-luciferase small interfering RNA in a cationic lipo-
some formulation 2 days before GBV-B infection (Yokota et al.,
2007). Irrespective of the partial suppression of the viral growth,
humoral immune responses were delayed and consequently the
individual developed chronic infection. Taken together, it is rea-
sonable to assume that the viral persistence in marmosets may
be closely associated with inefﬁcient antiviral immune responses
that are elicited at the periods of the lower viral loads. Previously,
we and others employed relatively higher amounts of GBV-B for
challenge in tamarins and marmosets. This could result in greater
viral loads in the acute phase than those in humans and chim-
panzees infected with HCV, followed by induction of efﬁcient
protective immunity and acute clearance. To clarify the mecha-
nisms by which chronic GBV-B infection is established, further
characterization of the differences in innate and acquired antiviral
immunity between individuals with acute clearance and chronic
infection will be needed.
Accumulating evidence suggests that escape mutations occur-
ring during the course of chronic HCV infection may lead to
evasion of humoral and cellular antiviral immunity (Bowen
and Walker, 2005a,b; Burke and Cox, 2010). Consistent with
these observations, we found that GBV-B acquired multiple
back or sequential non-synonymous mutations (e.g., G250V>A,
S731L> S, E2346G> E in Cj05-002; and V254A>V, I285V> I,
L495S> L,T735A>T,F2135L> F> S inCj05-004) in the chroni-
cally infectedmarmosets.Highly selectivenon-synonymousmuta-
tions were identiﬁed especially in E1, but such mutations were
rarely observed in core (Figures 4 and 5). Moreover, the non-
synonymous mutations in the E1 and NS3 regions occurred
throughout the observation periods in Cj05-004 with chronic
GBV-B infection, which had not been identiﬁed previously
(Simons et al., 1995; Bukh et al., 1999; Sbardellati et al., 2001;
Martin et al., 2003;Nam et al., 2004; Kyuregyan et al., 2005;Weath-
erford et al., 2009; Takikawa et al., 2010). Together with the ﬁnding
that the rates of both synonymous and non-synonymous muta-
tions were similar to those observed in cases of HCV (Ogata et al.,
1991; Fernandez et al., 2004), these results strongly suggest that
efﬁcient and selective evasion from immune pressures may result
in long-term persistent GBV-B infection and subsequent chronic
hepatitis. Further analyses on the functional signiﬁcance of the
non-synonymous mutations will clarify this possibility.
It is surprising that in Cj05-004, the antibody titer to NS3
was observed to steadily increase after week 10 p.i. irrespective
of the scarce viral loads over 1 year p.i., including the bipartite
FIGURE 5 |The frequency of the non-synonymous mutations in the
viral genome sequences amplified from plasma of the marmosets
persistently infected with GBV-B. (A,B)The accumulated frequency of
the non-synonymous mutations per total amino acid numbers of each viral
protein at multiple time points are illustrated [(A) at weeks 45, 104, and 135
in Cj05-002; (B) weeks 33, 88, and 141 in Cj05-004]. To compare the
frequency between the two marmosets, the data at week 229 p.i. in
Cj05-004 are omitted. (C)The ratio of the non-synonymous mutations per
total numbers of nucleotide mutations identiﬁed at weeks 45, 104, and 135
in Cj05-002 and at weeks 33, 88, and 141 in Cj05-004 in each viral gene. To
compare the frequency between the two marmosets, the data at week 229
p.i. in Cj05-004 are omitted.
periods of weeks 4–26 and 34–58 p.i. when the virus was unde-
tectable (Figure 1). Considering that three spikes of ALT levels
were observed during these periods, our results suggest that anti-
genic stimulation by the lower level of viral growth in the liver,
which was below detectable levels in blood, may induce the anti-
body and cytotoxic T-cell responses. In addition, during longitu-
dinal analyses of monkeys experimentally infected with GBV-B,
it is important to comprehensively evaluate multiple parame-
ters, including viral loads, serum enzymes, and antibodies against
core and NS3 proteins, to deﬁne whether virus-infected monkeys
that produce no detectable viremia for a period of time have
cleared the virus or are experiencing a latent period of chronic
infection.
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APPENDIX
MATERIALS AND METHODS
Liver samples obtainedbynecropsy from theGBV-B-infectedmar-
mosets were histopathologically analyzed as described in Section
“Materials and Methods.” Elastica–van Gieson staining was per-
formed to evaluate ﬁbrosis according to a standard laboratory
protocol. To detect CD3 and CD20 antigens, liver samples were
ﬁxed in 10% neutral buffered formalin and embedded in parafﬁn
wax. Sections were deparafﬁnized by pretreatment with 0.5%peri-
odic acid and then subjected to antigen retrieval with citric acid
FIGUREA1 | Histopathological and immunohistochemical analyses of
the liver from Cj05-004 at week 229 p.i.
buffer and heating in an autoclave for 10min at 121˚C. Sections
were then incubated free ﬂoating in the monoclonal antibody
solution for CD20 (DAKO) and CD3 (DAKO) overnight at 4˚C.
Following brief washes with buffer, the sections were sequentially
incubatedwith biotinylated goat anti-mouse IgG (1:400), followed
by streptavidin–biotin–horseradish peroxidase complex (sABC
kit; DAKO, Denmark). Immunoreactive elements were visual-
ized by treating the sections with 3,3′-diaminobenzidine tetroxide
(Dojin Kagaku, Japan). The sections were then counterstained
with hematoxylin.
Frontiers in Microbiology | Virology December 2011 | Volume 2 | Article 240 | 8
